Re: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial

Samir S. Taneja

doi:10.1016/j.juro.2012.04.069

Re: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial

Samir S. Taneja

Biomedical Engineering

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	412-413
Number of pages	2
Journal	Journal of Urology
Volume	188
Issue number	2
DOIs	https://doi.org/10.1016/j.juro.2012.04.069
State	Published - Aug 2012

ASJC Scopus subject areas

Urology

Access to Document

10.1016/j.juro.2012.04.069

Cite this

@article{59c34a84b7bc46049af7d8afc3a84581,

title = "Re: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial",

author = "Taneja, {Samir S.}",

year = "2012",

month = aug,

doi = "10.1016/j.juro.2012.04.069",

language = "English (US)",

volume = "188",

pages = "412--413",

journal = "Investigative Urology",

issn = "0022-5347",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Re

T2 - Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial

AU - Taneja, Samir S.

PY - 2012/8

Y1 - 2012/8

UR - http://www.scopus.com/inward/record.url?scp=84863712300&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863712300&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2012.04.069

DO - 10.1016/j.juro.2012.04.069

M3 - Comment/debate

C2 - 22784716

AN - SCOPUS:84863712300

SN - 0022-5347

VL - 188

SP - 412

EP - 413

JO - Investigative Urology

JF - Investigative Urology

IS - 2

ER -

Re: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this